EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ADAMTS13 in the New Era of TTP

Anna Papakonstantinou, Panagiotis Kalmoukos iD, Aikaterini Mpalaska, Evaggelia-Evdoxia Koravou, Eleni Gavriilaki iD

International Journal of Molecular Sciences · 26.07.2024 · 25 (15) · 8137

DOI: 10.3390/ijms25158137 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.07.2024. Verfasst von Anna Papakonstantinou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: ADAMTS13 Protein, Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening, often immune-mediated disease that affects 2–13 persons per million per year. Hemolytic anemia, thrombocytopenia, and end-organ damage due to the formation of microthrombi are characteristic of TTP. ADAMTS13 is a disintegrin, metalloproteinase, cleaving protein of von Willebrand factor (VWF) that processes the VWF multimers to prevent them from interacting with platelets and, in turn, to microvascular thrombosis. Prompt diagnosis of TTP is critical yet challenging. Thrombotic microangiopathies have similar clinical presentation. Measurement of ADAMTS13 activity helps in the differential diagnosis. Less than 10% ADAMTS13 activity is indicative of TTP. Laboratory ADAMTS13 activity assays include incubating the test plasma with the substrate (full-length VWM multimers) and detection with direct or indirect measurement of the cleavage product. The purpose of this study is to examine the diagnostic potential, advantages, and weaknesses of the ADAMTS13 potency in TTP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 ProteinPurpura, Thrombotic ThrombocytopenicHumansvon Willebrand Factor

Stichwörter der Autor:innen

ADAMTS13 cleaving proteasecaplacizumabplasmic scorerecombinant ADAMTS13rituximabthrombotic thrombocytopenic purpura

Substanzen

ADAMTS13 ProteinADAMTS13 protein, humanvon Willebrand Factor

Autor:innen und Institutionen

  • Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.

ORCID-Profile: Panagiotis Kalmoukos, Eleni Gavriilaki

Zitieren

APA

Papakonstantinou, A., Kalmoukos, P., Mpalaska, A., Koravou, E. E., & Gavriilaki, E. (2024). ADAMTS13 in the New Era of TTP. International Journal of Molecular Sciences, 25(15), 8137. https://doi.org/10.3390/ijms25158137

Vancouver

Papakonstantinou A, Kalmoukos P, Mpalaska A, Koravou EE, Gavriilaki E. ADAMTS13 in the New Era of TTP. International Journal of Molecular Sciences. 2024;25(15):8137. doi:10.3390/ijms25158137

BibTeX
@article{Papakonstantinou2024,
  author = {Papakonstantinou, Anna and Kalmoukos, Panagiotis and Mpalaska, Aikaterini and Koravou, Evaggelia-Evdoxia and Gavriilaki, Eleni},
  title = {ADAMTS13 in the New Era of TTP},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8137},
  doi = {10.3390/ijms25158137}
}
Kostenlos starten →